HALO HALOZYME THERAPEUTICS, INC. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$78.6

Period return

+7.31 (+10.25%)

Volume

1.2M

2026-07-21O $76.96 H $78.64 L $76.96 C $78.6MA5 $77.37MA20 $76.79MA60 $70.86MA120 $70.02

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 04.Highin 14 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.09%
2026. 05. 13.LowBUY2 months ago
Morgan Stanley: Overweight
US analyst rating / recommendation change.
2026. 04. 29.LowBUY3 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 02. 20.LowBUY5 months ago
Benchmark: Buy
US analyst rating / recommendation change.
2026. 02. 19.LowHOLD5 months ago
Wells Fargo: Equal-Weight
US analyst rating / recommendation change.
2026. 01. 09.LowBUY6 months ago
TD Cowen: Buy
US analyst rating / recommendation change.
2025. 12. 19.LowBUY7 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 11. 28.LowBUY8 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 11. 19.LowHOLD8 months ago
Goldman Sachs: Neutral
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $83.9 · 10 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 04.	After market close (AMC)	$1.82	—	—	$403.98M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$0.93	—	—	$264.86M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$2.37	—	—	$717.32M	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$1.32	—	—	$427.23M	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	1,584,961	$102.44M	0.09%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	717,369	$48.28M	0.08%	—	New position

HALOZYME THERAPEUTICS, INC.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 13.	Morgan Stanley	—	Maintain	Overweight → Overweight	—	Morgan Stanley: Overweight
2026. 04. 29.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 02. 20.	Benchmark	—	Maintain	Buy → Buy	—	Benchmark: Buy
2026. 02. 19.	Wells Fargo	—	Maintain	Equal-Weight → Equal-Weight	—	Wells Fargo: Equal-Weight
2026. 01. 09.	TD Cowen	—	Maintain	Buy → Buy	—	TD Cowen: Buy
2025. 12. 19.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy